NCT03075267 - Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects | Biotech Hunter

Enrollment

96

Participants

Timeline

Start Date

April 17, 2017

Primary Completion Date

September 5, 2017

Study Completion Date

September 5, 2017

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

PT010 (BGF MDI) 320/14.4/9.6 µg

A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.

DRUG

PT010 (BGF MDI) 160/14.4/9.6 µg

A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.

DRUG

PT003 (GFF MDI) 14.4/9.6 µg

A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.

Trial Locations (1)

200031

Research Site, Shanghai